Vasopressin
وازوپرسین
🧬 Systemic Hormonal Preparations, Excl. Sex Hormones And InsulinsVasopressor (V1 agonist)
Market / country: 🇺🇸 USA
Vasostrict (US)
🧮 Dose calculator
Shock (septic, cardiogenic, acute hypotension) — ICU · Regimen source: FDA Vasostrict · 2.2
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Hypersensitivity to vasopressin (multiple-dose vial: or chlorobutanol). FDA Vasostrict · 4
Formulations
- 20 units/100 mL premixed (0.2 units/mL) — injection 🇺🇸 USA FDA Vasostrict · 3
- 40 units/100 mL premixed (0.4 units/mL) — injection 🇺🇸 USA FDA Vasostrict · 3
- 60 units/100 mL premixed (0.6 units/mL) — injection 🇺🇸 USA FDA Vasostrict · 3
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Vasostrict · 8.1
“Risk Summary There are no available data on Vasostrict ® use in pregnant women to inform a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Vasostrict · 8.2
“There are no data on the presence of vasopressin injection in either human or animal milk, the effects on the breastfed infant, or the effects on milk production.”
- 👶 ChildrenSafety not established
Label: safety and effectiveness in children have not been established. FDA Vasostrict · 8.4
“Safety and effectiveness of Vasostrict ® in pediatric patients with vasodilatory shock have not been established.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Vasostrict · 8.5
“In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy [see Warnings and Precautions (5) , Adverse Reactions (6) , and …”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)NDA204485
- DailyMed (FDA label)FDA Vasostrict
- MedlinePlus (NIH)❌ None
- WHO ATC/DDDH01BA01
- Darooyab (Iran)Vasopressin
🇮🇷 Registered in Iran Darooyab · G-2727/Vasopressin
Dosage forms with Iranian generic codes, per Darooyab.
- 01277 · VASOPRESSIN 20PRESSOR U/ML AMP · آمپول واسوپرسسین ۲۰ پرسسور واحد / میلیلیتر
- 18427 · VASOPRESSIN 40PRESSOR U/2ML AMP · آمپول واسوپرسسین ۴۰ پرسسور واحد / ۲ میلیلیتر
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Vasostrict · 3FDA Vasostrict · 2.2FDA Vasostrict · 4FDA Vasostrict · SPL approval / marketing categoryFDA Vasostrict · 8.1FDA Vasostrict · 8.2FDA Vasostrict · 8.4FDA Vasostrict · 8.5
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-2727/Vasopressin
- Clinical review⚠ Unverified